Bioinnovation Enterprise: An engine driving breakthrough therapies
- PMID: 26785918
- PMCID: PMC4721259
- DOI: 10.1002/cpt.272
Bioinnovation Enterprise: An engine driving breakthrough therapies
Abstract
Biological advances have radically expanded our insights into the underpinnings of health and disease. New knowledge has formed the substrate for translation-expedited in turn by the biotechnology and pharmaceutical industry into novel therapeutic solutions impacting the management of patients and populations. Indeed, this Bioinnovation Enterprise has become the dominant growth sector in drug development and the engine driving the translation of breakthrough therapies worldwide. This annual Therapeutic Innovations issue highlights recent exceptional advances by the Bioinnovation Enterprise in translating molecular insights in pathobiology into transformative therapies.
© 2015 American Society for Clinical Pharmacology and Therapeutics.
References
-
- Hohl RJ. Drug development (and academic medicine): charting the course forward. Clin Pharmacol Ther. 2014;96:519–22. - PubMed
-
- Honig P, Huang SM. Intelligent pharmaceuticals: beyond the tipping point. Clin Pharmacol Ther. 2014;95:455–9. - PubMed
-
- Waldman SA, Terzic A. Molecular insights provide the critical path to disease mitigation. Clin Pharmacol Ther. 2014;95:3–7. - PubMed
-
- Smith BP, Huang SM. Novel approaches to address challenges in global drug development. Clin Pharmacol Ther. 2015;97:196–9. - PubMed
-
- Wagner JA, Atkinson AJ., Jr Measuring Biomarker Progress. Clin Pharmacol Ther. 2015;98:2–5. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
